Skip to main content
. Author manuscript; available in PMC: 2022 Jun 24.
Published in final edited form as: Cell. 2021 Jun 1;184(13):3486–3501.e21. doi: 10.1016/j.cell.2021.05.001

Figure 6. Protective efficacy of lead nAbs and nAb combinations in two murine models of lethal CCHFV challenge.

Figure 6.

(A-B) Type I IFN α/β/ R−/− (IFNAR1-KO) mice were treated with the indicated mAbs or mAb combinations 1 day prior to challenge with CCHFV IbAr10200. (n = 10 mice per group) (A) Survival curves (vehicle versus test mAb) were compared by Mantel-Cox test (*** P < 0.001, ** P < 0.01). (B) Associated mean weight loss data are shown. (C-D) Stat1−/− mice were challenged with CCHFV Turkey/2004 and then treated with single doses of the indicated mAbs or vehicle at 30 min post-exposure. (n = 5 mice per group) (C) Survival curves (vehicle versus test mAb) were compared by Mantel-Cox test (*** P < 0.001, ** P < 0.01). (D) Associated mean weight loss data are shown. (E-H) IFNAR1-KO mice were exposed to CCHFV IbAr10200 and treated with the indicated mAbs or mAb combinations at 1 day post-challenge. (n = 10 mice per group) (E, G) Survival curves (vehicle versus test mAb) were compared by Mantel-Cox test (*** P < 0.001, ** P < 0.01). (F, H) Associated mean weight loss data are shown.